OM
ZNTL icon

Opaleye Management’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Opaleye Management’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.85M Hold
1,412,656
– – 0.62% 30
2026
Q1 		$3.31M Buy
1,412,656
+11,750
+0.8% +$30.3K 0.44% 40
2025
Q4 		$1.89M Buy
1,400,906
+1,084,356
+343% +$1.58M 0.25% 46
2025
Q3 		$478K Sell
316,550
-1,607,750
-84% -$2.41M 0.07% 40
2025
Q2 		$2.23M Sell
1,924,300
-60,700
-3% -$80.1K 0.45% 33
2025
Q1 		$3.16M Buy
1,985,000
+217,500
+12% +$469K 0.7% 29
2024
Q4 		$5.36M Buy
1,767,500
+800,500
+83% +$2.62M 0.94% 22
2024
Q3 		$3.56M Buy
+967,000
New +$3.51M 0.59% 30
2024
Q2 		– Sell
-200,000
Closed -$3.15M – 60
2024
Q1 		$3.15M Buy
+200,000
New +$2.75M 0.69% 36
2023
Q1 		– Sell
-167,500
Closed -$3.37M – 46
2022
Q4 		$3.37M Buy
+167,500
New +$3.6M 1.17% 25

Other funds holding ZNTL

5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return

Opaleye Management's ZNTL Position: Q2 2026 in Review

Opaleye Management held its Zentalis Pharmaceuticals (ZNTL) position steady in Q2 2026 at 1,412,656 shares worth $6.85M. The position accounts for 0.62% of the portfolio, ranked #30.

Opaleye Management first reported a position in ZNTL in Q4 2022 and has held it in 10 quarters since. 114 funds tracked by Wall St. Rank hold ZNTL as of Q2 2026.

  • Opaleye Management held 1,412,656 shares of Zentalis Pharmaceuticals worth $6.85M as of Q2 2026.
  • Opaleye Management left its Zentalis Pharmaceuticals share count unchanged in Q2 2026.
  • Zentalis Pharmaceuticals made up 0.62% of Opaleye Management's portfolio in Q2 2026, its #30 holding.
  • Opaleye Management first reported a position in Zentalis Pharmaceuticals in Q4 2022 and has held it in 10 quarters since.
  • 114 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q2 2026.

Based on Opaleye Management's 13F filing for Q2 2026, filed 14 Aug 2026.